At AS&NL, our goal is to provide innovative solutions to society, always keeping the patient at the centre of all our activities.
For this reason, we developed the project to launch PRP PROFACTOR®.
Joan Casadesús, Co-founder and commercial director of ASNL
Therefore, PRP PROFACTOR® is administered 15 days prior to each injection, taking into account the half-life of platelets (7-10 days) and the time factor in order to influence their composition.
Find out more about the theoretical framework and results of our clinical trial, as well as the mechanism of action of our product, endorsed by our experts.
Theoretical framework
History of the field of study
Our innovation
Clinical trial results
